NGM's NGM282 meets in Phase II data for NASH

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported data from a single-blind Phase II trial in 19 non-alcoholic steatohepatitis (NASH) patients showing that once-daily subcutaneous 3 mg NGM282 met the primary

Read the full 310 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE